Dalantercept

DB14988InvestigationalProtein Based Therapies

Dalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).

Mechanism: Pharmacologically active on Growth/differentiation factor 2 and Bone morphogenetic protein 10
Curator reviewed
Code names: ACE-041

Resolves to

Compound

UNIIEGC16R10V0CAS1186210-24-1

Targets

Q9UK05GDF2O95393BMP10

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

6Clinical trialsPhase, status and sponsor resolved per trial

7+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dalantercept, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account